<DOC>
	<DOCNO>NCT01374451</DOCNO>
	<brief_summary>This study estimate treatment effect everolimus combination pasireotide LAR relative everolimus alone progression-free survival ( PFS ) patient advance progressive PNET . A planned primary analysis complete data cut 02-Apr-2014 . The study meet primary objective , base progression-free survival ( PFS ) per local radiology assessment prematurely terminate last patient last visit 19-Feb-2015 . However , important note data reveal new safety concern . It decide stop study decision share study site 31-Jul-2014 .</brief_summary>
	<brief_title>Efficacy Everolimus Alone Combination With Pasireotide LAR Advanced PNET</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Advanced histologically confirm well differentiate pancreatic neuroendocrine tumor Progressive disease within last 12 month Measurable disease per RECIST Version 1.0 determine multiphase MRI triphasic CT Patients currently require somatostatin analog treatment Prior therapy mTOR inhibitor pasireotide Patients 2 prior systemic treatment regimens Previous cytotoxic chemotherapy , target therapy , somatostatin analog , biotherapy within last 4 week Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pancreatic</keyword>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>PNET</keyword>
	<keyword>Pasireotide</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Advanced progressive pancreatic neuroendocrine tumor</keyword>
</DOC>